ArticleBMC ophthalmology2025
Effect of intraoperative mitomycin C application at different concentrations on corneal densitometry after SmartSurf
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeThis study aimed to investigate corneal densitometry (CD), visual, and refractive outcomes after transepithelial photorefractive keratectomy (TPRK) using smart pulse technology (SPT), known as the SmartSurface procedure, in patients treated with or without mitomycin C (MMC) at concentrations of 0.01% and 0.02%.
methodsThis retrospective study analyzed 138 eyes of 138 patients who underwent SmartSurface surgery and were categorized into three groups based on intraoperative MMC concentration: the MMC0.02 group (0.02% MMC), the MMC0.01 group (0.01% MMC), and the Control group (no MMC), with 46 eyes per group. Corneal haze, uncorrected distance visual acuity (UDVA), and spherical equivalent (SE) were assessed preoperatively and at 2 weeks, 1 month, and 3 months postoperatively. Corneal densitometry was performed across different concentric radial zones (0–2, 2–6, and 6–10 mm annulus) and layers (anterior, central, posterior, and total) using Scheimpflug imaging preoperatively and at the same postoperative time points.
resultsThree months after SmartSurface treatment, the incidence of haze was significantly lower in the MMC0.01 (6.52%) and MMC0.02 (4.35%) groups than in the Control group (15.22%) (P = 0.048 and P = 0.01, respectively). The MMC0.01 and MMC0.02 groups showed no significant differences in haze incidence (P = 0.244). Furthermore, no significant differences were observed in UDVA or SE among the three groups at any postoperative time point (all P > 0.05). In terms of corneal densitometry, three months after surgery, the central layer CD values in the 0–2 mm zone (MMC0.01: 14.48 ± 1.21 GSU vs. MMC0.02: 14.56 ± 1.01 GSU vs. Control: 15.23 ± 1.25 GSU) and the posterior layer CD values (MMC0.01: 11.49 ± 0.70 GSU vs. MMC0.02: 11.40 ± 0.70 GSU vs. Control: 11.96 ± 0.78 GSU) were significantly lower in both MMC groups compared to the Control group (all P < 0.05). Similarly, in the 2–6 mm zone, the posterior layer CD values (MMC0.01: 10.41 ± 0.75 GSU vs. MMC0.02: 10.38 ± 0.59 GSU vs. Control: 10.88 ± 0.71 GSU) and total layer CD values (MMC0.01: 13.39 ± 0.54 GSU vs. MMC0.02: 13.36 ± 0.49 GSU vs. Control: 13.65 ± 0.51 GSU) were significantly lower in both MMC groups than in the Control group (all P < 0.05). However, no significant differences in CD values were found between the MMC0.01 and MMC0.02 groups across any zone or layer (all P > 0.05).
conclusionBoth 0.01% and 0.02% MMC are similarly effective in preventing haze and enhancing corneal clarity following SmartSurface surgery. However, given the unproven long-term safety of MMC, its use at a lower concentration is advisable to avert potential complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.